ES2101865T3 - Igf-1 para mejorar el estado neural. - Google Patents

Igf-1 para mejorar el estado neural.

Info

Publication number
ES2101865T3
ES2101865T3 ES92917908T ES92917908T ES2101865T3 ES 2101865 T3 ES2101865 T3 ES 2101865T3 ES 92917908 T ES92917908 T ES 92917908T ES 92917908 T ES92917908 T ES 92917908T ES 2101865 T3 ES2101865 T3 ES 2101865T3
Authority
ES
Spain
Prior art keywords
nervous system
central nervous
igf
improve
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917908T
Other languages
English (en)
Inventor
Peter Gluckman
Karoly Nikolics
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Genentech Inc
Original Assignee
Auckland Uniservices Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19923685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2101865(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auckland Uniservices Ltd, Genentech Inc filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of ES2101865T3 publication Critical patent/ES2101865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Color Image Communication Systems (AREA)

Abstract

SE PRESENTA UN METODO PARA TRATAR LAS LESIONES O ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL QUE PREDOMINANTEMENTE AFECTAN LAS CELULAS NEURONALES GLIA Y/O NO COLINERGICAS QUE SE CARACTERIZA EN QUE COMPRENDE EL PASO DE INCREMENTAR LAS CONCENTRACIONES ACTIVAS DEL FACTOR DE CRECIMIENTO I SIMILAR A LA INSULINA Y/O ANALOGOS DEL MISMO EN EL SISTEMA NERVIOSO CENTRAL DEL PACIENTE. LA INVENCION TAMBIEN SUMINISTRA COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN EL FACTOR DE CRECIMIENTO I SIMILAR A LA INSULINA Y/O ANALOGOS DEL MISMO PARA SU ADMINISTRACION A UN PACIENTE DESPUES DE LOS DAÑOS NEURONALES, DICHAS COMPOSICIONES SON UTILES PARA MINIMIZAR LOS DAÑOS EN EL SISTEMA NERVIOS CENTRAL QUE DE OTRA FORMA SE PRODUCIRIAN SIGUIENDO A LA LESION.
ES92917908T 1991-08-01 1992-08-03 Igf-1 para mejorar el estado neural. Expired - Lifetime ES2101865T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ23921191 1991-08-01

Publications (1)

Publication Number Publication Date
ES2101865T3 true ES2101865T3 (es) 1997-07-16

Family

ID=19923685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917908T Expired - Lifetime ES2101865T3 (es) 1991-08-01 1992-08-03 Igf-1 para mejorar el estado neural.

Country Status (9)

Country Link
US (2) US5714460A (es)
EP (1) EP0597033B1 (es)
AT (1) ATE151293T1 (es)
CA (1) CA2114251C (es)
DE (1) DE69218948T2 (es)
DK (1) DK0597033T3 (es)
ES (1) ES2101865T3 (es)
GR (1) GR3023874T3 (es)
WO (1) WO1993002695A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
ES2140463T3 (es) * 1992-06-12 2000-03-01 Cephalon Inc Prevencion y tratamiento de la neuropatia periferica.
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
EP0735894A4 (en) 1993-12-23 1999-08-18 Auckland Uniservices Ltd COMPOSITION AND METHODS FOR IMPROVING THE OUTCOME OF NERVOUS SYSTEM CONDITIONS
US5656605A (en) * 1994-01-26 1997-08-12 Institute Of Molecular Biology, Inc. Device to promote drug-induced nerve regeneration
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5965531A (en) * 1995-08-31 1999-10-12 National Institutes Of Health Method of reducing perivascular lesions using insulin-like growth factor I
ATE236652T1 (de) * 1995-12-13 2003-04-15 Aurogen Inc Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
WO1999020299A1 (en) * 1997-10-17 1999-04-29 Spencer E Martin Human urinary incontinence and methods of treatment
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
AU751217B2 (en) * 1998-06-15 2002-08-08 Neuren Pharmaceuticals Limited Regulation of tyrosine hydroxylase
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
DK1141015T3 (da) * 1999-01-06 2010-01-25 Genentech Inc Insulin-lignende vækstfaktor (IGF) I-mutantvarianter
WO2001037855A2 (en) * 1999-10-27 2001-05-31 Chiron Corporation Temperature dependent neuronal rescue
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
ATE463252T1 (de) * 2000-08-29 2010-04-15 Aurogen Inc Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
ATE439378T1 (de) * 2001-02-09 2009-08-15 Genentech Inc Verfahren zur identifizierung von indirekten igf- 1-agonisten
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
AU2002324672B2 (en) 2001-09-18 2007-11-08 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
CA2538342C (en) 2003-09-12 2013-01-08 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
EP1670822A2 (en) * 2003-10-03 2006-06-21 Genentech, Inc. Igf binding proteins
US7220729B2 (en) * 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
JP2009533458A (ja) * 2006-04-14 2009-09-17 マサチューセッツ インスティテュート オブ テクノロジー 神経系の可塑性を媒介する分子経路の同定および変調
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
AU2007291501B2 (en) 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
WO2009121759A2 (en) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Use of pegylated igf-i variants for the treatment of neuromuscular disorders
BRPI0911266A2 (pt) * 2008-04-03 2015-09-29 Hoffmann La Roche ensaio de fator de crescimento similar à insulina peguilado
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CN106167789B (zh) * 2015-05-21 2020-08-04 中国科学院上海营养与健康研究所 低氧处理的间充质干细胞及其应用
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
AU2019271189A1 (en) 2018-05-15 2021-01-07 Lloyd Hung Loi TRAN Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5817623A (en) 1995-03-06 1998-10-06 Univ Colorado State Res Found Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0525056A (ja) * 1989-07-27 1993-02-02 Max Planck Inst Fuer Saikaiatorii 中枢神経系における神経成長因子合成の調節
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US20070078089A1 (en) 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II

Also Published As

Publication number Publication date
CA2114251A1 (en) 1993-02-18
GR3023874T3 (en) 1997-09-30
CA2114251C (en) 2007-11-06
DE69218948T2 (de) 1997-07-31
WO1993002695A1 (en) 1993-02-18
US5714460A (en) 1998-02-03
DE69218948D1 (de) 1997-05-15
USRE43982E1 (en) 2013-02-05
EP0597033A1 (en) 1994-05-18
DK0597033T3 (da) 1997-06-02
ATE151293T1 (de) 1997-04-15
EP0597033B1 (en) 1997-04-09

Similar Documents

Publication Publication Date Title
ES2101865T3 (es) Igf-1 para mejorar el estado neural.
HK1048058A1 (zh) 肝臟選擇性的藥用活性物
DE68911068T2 (de) EGF zur Vorbeugung von Gewebeschädigung nach Ischemie.
HK1003978A1 (en) Composition for the treatment of schizophrenia
CA2122058A1 (en) Tgf-beta to improve neural outcome
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
NO990088D0 (no) Farmas÷ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindamin
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
MY131805A (en) Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
ZA911496B (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
GR3031459T3 (en) Wound treatment employing biologically active peptides
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
BR9708287A (pt) Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
RU94041207A (ru) Средство для лечения заболеваний, поражающих нервную систему
PT817646E (pt) Metodos de tratamento da inflamacao e formulacoes para esse fim
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
EP0744176A3 (en) Methods for inhibiting bone loss
EP0790250A3 (en) Inhibitors of biogenic amine transporters
CO5031290A1 (es) Formulacion lo
MD1296G2 (ro) Metoda Nicolau de tratament al lichenului plan bucal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 597033

Country of ref document: ES